Avalo Therapeutics, Inc. - Common Stock AVTX 深 沪
等待开盘 09-17 09:30:00 美东时间
9.76
-0.380
-3.75%
华盛通- 最 高10.33
- 今 开10.20
- 成交量 29.43万股
- 最 低 9.54
- 昨 收 10.14
- 总市值 782.37万
- 52周最高 16.00
- 市盈率 静 --
- 换手率 36.72%
- 52周最低 3.39
- 委 比 98.78%
- 总股本 80.16万
- 历史最高 22032.00
- 量 比 2.29
- 振 幅 7.79%
- 历史最低 3.39
- 每 手 1
- 风险率 5.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Avalo Therapeutics (AVTX) Gets a Buy from Oppenheimer
In a report released today, Leland Gershell from Oppenheimer reiterated a Buy r...
09-15 19:55
Real-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System
AVITA Medical's study shows that the RECELL® System reduces hospital stays by 36% for adults with deep second-degree burns, saving over $42,000 per patient and improving hospital efficiency. Presented at the 2025 European Burn Association Congress in Berlin, the research highlights RECELL's clinical and economic benefits in modern burn management.
09-04 11:45
Cantor Fitzgerald Initiates Coverage On Avalo Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Overweight rating.
08-15 20:55
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical invites shareholders and investors to an investor webinar on August 14, 2025, at 9 AM AEDT (August 13 at 4 PM PDT). The webinar will cover Q2 2025 financial and business results, with a Q&A session. Register at [link]. AVITA, a leader in acute wound care, highlights its FDA-approved RECELL System for burn and trauma wound treatment, along with other products like PermeaDerm and Cohealyx. A replay will be available post-event. For mo...
08-10 23:00
Avalo Therapeutics Q2 EPS $(1.92) Misses $(1.42) Estimate; Cash, Cash equivalents And Short-term Investments Were $113.3M As Of June 30
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(1.92) per share which missed the analyst consensus estimate of $(1.42) by 35.5 percent. This is a 86.35 percent increase over losses of $(14.07) per share
08-07 19:17
AVITA Medical to Announce Second Quarter 2025 Financial Results
AVITA Medical, Inc. announced it will report its Q2 2025 financial results after U.S. markets close on August 7, 2025. The company will host a conference call and webcast on August 8, 2025, at 6:30 a.m. Australian Eastern Standard Time (1:30 p.m. Pacific Time) to discuss its financial results and recent business highlights. The live webcast and replay will be available on the company's Investor Relations website. AVITA Medical is a leading therap...
07-28 20:05
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics, a clinical-stage biotech company focused on treating immune dysregulation, announced that its management will participate in two investor conferences: the HCW Annual Inflammation & Immunology Virtual Conference on June 30, 2025, and the BTIG Virtual Biotechnology Conference 2025 on July 29-30, 2025. The company’s lead asset, AVTX-009, is a humanized monoclonal antibody targeting IL-1β for inflammatory diseases. Webcasts and re...
06-23 11:00
Avalo Therapeutics Highlights Potential of AVTX-009 in HS
The latest announcement is out from Avalo Therapeutics ( ($AVTX) ). On June 20,...
06-20 19:28
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
Avalo Therapeutics has appointed Rita Jain, M.D., a leading rheumatologist with over two decades of experience in biopharma, to its Board of Directors. Jain's expertise in clinical development and regulatory affairs will support the advancement of AVTX-009, a Phase 2 anti-IL-1β monoclonal antibody targeting hidradenitis suppurativa (HS) and other inflammatory diseases. AVTX-009 inhibits IL-1β, a key driver of inflammation, with potential applicat...
06-18 11:00
AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL
AVITA Medical highlights data showing reduced hospital stay for burn patients treated with its RECELL technology, supported by a study analyzing over 6,300 patients. The spray-on skin cell therapy reduces hospital stays by 6.2 days (35.7%) and saves $300 million over five years compared to traditional grafting. The study underscores RECELL’s clinical and economic benefits, with the technology used in over 130 U.S. burn centers.
06-09 13:00
